Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs IV arsenic trioxide in acute promyelocytic leukemia
NCT07296445Phase 3Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 3 trial of arsenic trioxide in acute promyelocytic leukemia (APL). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
arsenic trioxide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT07296445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296445.